Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01758042 · ClinicalTrials.gov registry record · NA
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
A NA study of Multiple Myeloma and Chronic Kidney Disease, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01758042 is a NA study of Multiple Myeloma and Chronic Kidney Disease that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01758042, a NA study of Multiple Myeloma and Chronic Kidney Disease, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney rejection and less need for long-term use of anti-rejection drugs. Traditionally, very strong cancer treatment drugs (chemotherapy) and radiation are used to prepare a subject's body for bone marrow transplant. This is associated with a high risk for serious complications, even in subjects without kidney disease. This therapy can be toxic to the liver, lungs, mucous membranes, and intestines. Additionally, it is believed that standard therapy may be associated with a higher risk of a complication called graft versus host disease (GVHD) where the new donor cells attack the recipient's normal body. Recently, less intense chemotherapy and radiation regimens have been employed (these are called reduced intensity regimens) which cause less injury and GVHD to patients, and thus, have allowed older and less healthy patients to undergo bone marrow transplant. In this study, a reduced intensity regimen of chemotherapy and radiation will be used with the intent of producing fewer toxicities than standard therapy. Typical therapy following a standard kidney transplant includes multiple lifelong medications that aim to prevent the recipient's body from attacking or rejecting the donated kidney. These are called immunosuppressant drugs and they work by "quieting" the recipient's immune system to allow the donated kidney to function properly. One goal in our study is to decrease the duration you
Conditions Studied
Interventions
- PROCEDURE Haploidentical Bone Marrow/Kidney
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-11 |
| Est. Completion | 2025-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01758042
The ClinicalTrials.gov registry entry for NCT01758042 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Haploidentical Bone Marrow/Kidney is the first listed.
NCT01758042 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01758042 about?
NCT01758042 is a clinical study titled "Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders". The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the ...
What is the current status of trial NCT01758042?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-11. Estimated completion is 2025-07.
What conditions does trial NCT01758042 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Kidney Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Aplastic Anemia.
What interventions are being tested in trial NCT01758042?
The interventions under investigation include: Haploidentical Bone Marrow/Kidney (PROCEDURE).
Who is sponsoring clinical trial NCT01758042?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01758042 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.